Geron is no longer funding development of the stem cell programs. On October 1, 2013, Geron closed the transaction to divest its human embryonic stem cell assets and autologous cellular immunotherapy program to Asterias Biotherapeutics, Inc. In connection with the divestiture, Geron received 6,537,779 shares of Asterias Series A common stock. On August 15, 2014, Geron completed the distribution of the Asterias Series A common stock to eligible Geron stockholders. Click here for more information.